IP Verse

Cancer Patient Selection For Administration Of Wnt Signaling Inhibitors Using Rnf43 Mutation Status

Patent No. EP2820151 (titled "Cancer Patient Selection For Administration Of Wnt Signaling Inhibitors Using Rnf43 Mutation Status") was filed by IRM on Feb 22, 2013. The application was issued on Mar 25, 2020.

Patent Summary

Patent Family

Patent Family

Patent Oppositions (2)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentative
BOEHRINGER INGELHEIM RCVDec 15, 2020D YOUNG
BOEHRINGER INGELHEIMDec 15, 2020D YOUNG

Dossier Documents

The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents

EP2820151

IRM
Application Number
EP13707527A
Filing Date
Feb 22, 2013
Status
Granted And Under Opposition
Feb 21, 2020
Publication Date
Mar 25, 2020
External Links
Slate, Register , Google Patents